An experimental cancer vaccine from Moderna based on mRNA technology has been shown to work against melanoma, sending Moderna shares more than 20% higher.
By Julie Steenhuysen and Michael Erman CHICAGO (Reuters) - An experimental personalized melanoma vaccine developed by Moderna Inc given with Merck & C.
A combination of Moderna Inc s experimental melanoma vaccine and Merck & Co s blockbuster immunotherapy Keytruda cut the risk of skin cancer s recurrence or death by 44% compared with Keytruda
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44% thefrontierpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thefrontierpost.com Daily Mail and Mail on Sunday newspapers.